EGFR and non-small cell lung carcinoma: As in non-squamous NSCLC, druggable genetic alterations include EGFR mutations (target of EGFR TKI e.g. Osimertinib, Afatinib), ALK translocations (target of ALK inhibitors e.g. Alectinib, Brigatinib), and ROS1 translocations (target of ROS1 inhibitors e.g. Crizotinib, Entrectinib) further molecular testing was performed.